Safety, Tolerability, and Pharmacokinetics of KNS‐760704 (Dexpramipexole) in Healthy Adult Subjects
Identifieur interne : 000160 ( Main/Exploration ); précédent : 000159; suivant : 000161Safety, Tolerability, and Pharmacokinetics of KNS‐760704 (Dexpramipexole) in Healthy Adult Subjects
Auteurs : Bozik [États-Unis] ; Mather [États-Unis] ; Kramer [États-Unis] ; Gribkoff [États-Unis] ; Ingersoll [États-Unis]Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2011-08.
English descriptors
- KwdEn :
Abstract
Dexpramipexole (KNS‐760704; [6R]‐4,5,6,7‐tetrahydro‐N6‐propyl‐2,6‐benzothiazole‐diamine) is a novel synthetic amino‐benzothiazole in development for the treatment of amyotrophic lateral sclerosis (ALS). Preclinical studies have shown that dexpramipexole is neuroprotective in vitro and in vivo, is highly orally bioavailable and water soluble, and rapidly achieves and maintains high central nervous system concentrations relative to plasma. Two phase 1 clinical studies were conducted to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of dexpramipexole in 54 healthy male and female adults. The effect of food on the single‐dose PK of dexpramipexole was also evaluated. Single doses (50 mg, 150 mg, or 300 mg) and multiple doses (50 mg twice daily, 100 mg twice daily, or 150 mg twice daily) of dexpramipexole over 4.5 days were safe and well tolerated. Dexpramipexole was rapidly absorbed, with time to maximum plasma concentration ranging from 1.8 to 2.6 hours and half‐life ranging from 6.4 to 8.1 hours under fasted conditions, and was mostly eliminated in urine as unchanged parent drug (84%–90% of dose). Food had no effect on the single‐dose PK of dexpramipexole. These findings support the ongoing development of dexpramipexole for the treatment of ALS and further evaluation of the compound's therapeutic potential in other neurodegenerative diseases.
Url:
DOI: 10.1177/0091270010379412
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety, Tolerability, and Pharmacokinetics of KNS‐760704 (Dexpramipexole) in Healthy Adult Subjects</title><author><name sortKey="Bozik" sort="Bozik" uniqKey="Bozik" last="Bozik">Bozik</name></author><author><name sortKey="Mather" sort="Mather" uniqKey="Mather" last="Mather">Mather</name></author><author><name sortKey="Kramer" sort="Kramer" uniqKey="Kramer" last="Kramer">Kramer</name></author><author><name sortKey="Gribkoff" sort="Gribkoff" uniqKey="Gribkoff" last="Gribkoff">Gribkoff</name></author><author><name sortKey="Ingersoll" sort="Ingersoll" uniqKey="Ingersoll" last="Ingersoll">Ingersoll</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FEE067F38142AF3ABB111BA526B84BCB961B9153</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1177/0091270010379412</idno><idno type="url">https://api.istex.fr/document/FEE067F38142AF3ABB111BA526B84BCB961B9153/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002F56</idno><idno type="wicri:Area/Main/Curation">002B66</idno><idno type="wicri:Area/Main/Exploration">000160</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety, Tolerability, and Pharmacokinetics of KNS‐760704 (Dexpramipexole) in Healthy Adult Subjects</title><author><name sortKey="Bozik" sort="Bozik" uniqKey="Bozik" last="Bozik">Bozik</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Knopp Neurosciences, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Mather" sort="Mather" uniqKey="Mather" last="Mather">Mather</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Knopp Neurosciences, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Kramer" sort="Kramer" uniqKey="Kramer" last="Kramer">Kramer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Kramer Consulting LLC, North Potomac</wicri:cityArea></affiliation></author><author><name sortKey="Gribkoff" sort="Gribkoff" uniqKey="Gribkoff" last="Gribkoff">Gribkoff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Knopp Neurosciences, Pittsburgh</wicri:cityArea></affiliation></author><author><name sortKey="Ingersoll" sort="Ingersoll" uniqKey="Ingersoll" last="Ingersoll">Ingersoll</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Knopp Neurosciences, Pittsburgh</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Clinical Pharmacology</title><idno type="ISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-08">2011-08</date><biblScope unit="volume">51</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1177">1177</biblScope><biblScope unit="page" to="1185">1185</biblScope></imprint><idno type="ISSN">0091-2700</idno></series><idno type="istex">FEE067F38142AF3ABB111BA526B84BCB961B9153</idno><idno type="DOI">10.1177/0091270010379412</idno><idno type="ArticleID">JCPH5437</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-2700</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>(R)‐(+)‐pramipexole,(6R)‐4,5,6,7‐tetrahydro‐N6‐propyl‐2,6‐benzothiazole‐diamine</term><term>KNS‐760704</term><term>amyotrophic lateral sclerosis</term><term>dexpramipexole</term><term>motor neuron disease</term><term>neurology</term><term>pharmaceutical research and development</term><term>pharmacokinetics and drug metabolism</term><term>safety</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dexpramipexole (KNS‐760704; [6R]‐4,5,6,7‐tetrahydro‐N6‐propyl‐2,6‐benzothiazole‐diamine) is a novel synthetic amino‐benzothiazole in development for the treatment of amyotrophic lateral sclerosis (ALS). Preclinical studies have shown that dexpramipexole is neuroprotective in vitro and in vivo, is highly orally bioavailable and water soluble, and rapidly achieves and maintains high central nervous system concentrations relative to plasma. Two phase 1 clinical studies were conducted to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of dexpramipexole in 54 healthy male and female adults. The effect of food on the single‐dose PK of dexpramipexole was also evaluated. Single doses (50 mg, 150 mg, or 300 mg) and multiple doses (50 mg twice daily, 100 mg twice daily, or 150 mg twice daily) of dexpramipexole over 4.5 days were safe and well tolerated. Dexpramipexole was rapidly absorbed, with time to maximum plasma concentration ranging from 1.8 to 2.6 hours and half‐life ranging from 6.4 to 8.1 hours under fasted conditions, and was mostly eliminated in urine as unchanged parent drug (84%–90% of dose). Food had no effect on the single‐dose PK of dexpramipexole. These findings support the ongoing development of dexpramipexole for the treatment of ALS and further evaluation of the compound's therapeutic potential in other neurodegenerative diseases.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Bozik" sort="Bozik" uniqKey="Bozik" last="Bozik">Bozik</name></region><name sortKey="Gribkoff" sort="Gribkoff" uniqKey="Gribkoff" last="Gribkoff">Gribkoff</name><name sortKey="Ingersoll" sort="Ingersoll" uniqKey="Ingersoll" last="Ingersoll">Ingersoll</name><name sortKey="Kramer" sort="Kramer" uniqKey="Kramer" last="Kramer">Kramer</name><name sortKey="Mather" sort="Mather" uniqKey="Mather" last="Mather">Mather</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000160 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000160 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FEE067F38142AF3ABB111BA526B84BCB961B9153
|texte= Safety, Tolerability, and Pharmacokinetics of KNS‐760704 (Dexpramipexole) in Healthy Adult Subjects
}}
| This area was generated with Dilib version V0.6.23. |  |